DMX-200 for FSGS has orphan drug status which comes with a streamlined trial process that is compressed and therefore faster and cheaper, and well within Dimerix's capability to run. DMX-200 for DKD on the other hand will require a much longer and larger trial process that will take years and considerable expense to complete.
So the rationale would be for Dimerix to do the FSGS trials in-house without having to share any eventual revenue with a partner. This could be funded by further (modest) capital raises, or better still with upfront fees obtained from a Big Pharma partner who takes on the DKD Phase 3 trial in exchange for a share of future revenue. If the FSGS trial is successful, revenue will flow more quickly and fund future activities (such as DMX-700 development and perhaps dividends to shareholders).
- Forums
- ASX - By Stock
- DXB
- Ann: Quarterly Appendix 4C and Activities Report
Ann: Quarterly Appendix 4C and Activities Report, page-214
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add DXB (ASX) to my watchlist
(20min delay)
|
|||||
Last
52.0¢ |
Change
-0.030(5.45%) |
Mkt cap ! $285.8M |
Open | High | Low | Value | Volume |
54.5¢ | 55.5¢ | 51.5¢ | $1.982M | 3.739M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
8 | 82244 | 52.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
53.0¢ | 27153 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
7 | 72244 | 0.520 |
10 | 140912 | 0.515 |
12 | 194810 | 0.510 |
5 | 86136 | 0.505 |
27 | 274529 | 0.500 |
Price($) | Vol. | No. |
---|---|---|
0.530 | 27153 | 1 |
0.535 | 36844 | 3 |
0.540 | 111677 | 5 |
0.545 | 58651 | 3 |
0.550 | 61907 | 6 |
Last trade - 16.10pm 24/06/2024 (20 minute delay) ? |
Featured News
DXB (ASX) Chart |